Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists


320 Logue Avenue
Mountain View, CA 94043

Website Company Summary Management Team

CEO: Haru Morita (3/06)
Technology: Reiko Namikawa; Teikichi Aoyagi (07/31/2006)

Outside board: (May no longer be on the board) Yasuyuki Ishii (RIKEN Research Center for Allergy and Immunology team leader) Shirley Clayton (Abmaxis Former President/CEO) Hiroki Narita (NIF SMBC Ventures Deputy General Manager)

Business description: REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. In addition to its potential for GvHD, MultiVax is a therapeutic candidate for autoimmune diseases such as Multiple Sclerosis (MS) and Systemic Lupus, in which down-regulation of and/or dysfunction of regulatory T-cells lead to serious up-regulation of immunity against the auto-antigen. reVax is the company’s second proprietary technology platform, which works by modulating the immune system by enhancing antigen-specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis and MS, where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California.

Rounds: 2
Recent Fundings: May 2008   Feb 2007
Capital raised: 12.2M
Last Round: 8.0M
Ownership: Private  
VCs include: Icon Ventures CSK Venture Capital Orix Capital ;  Japan Asia Investment Co. ;  NIF SMBC Ventures Co. ;  Yasuda Enterprise Development Co. ;  New Business Investment Co. ;  Fund Creation Co. ;  Mitsubishi UFJ Capital Co.

Last Tweets


Last Mentions

Record updated: Dec 2008
Sector: Biotech
Year Founded: 2006
Rounds: 2
Recent Fundings: May 2008   Feb 2007
Capital Raised: 12.2M
Last Round: 8.0M
Ownership: Private